ComparisonInterventions

Hormone Therapy vs Non-Hormonal Treatment for Menopause

The most effective option, and the alternatives that are real

Menopausal Hormone TherapyOestrogen ± progestogen

Non-Hormonal TreatmentFezolinetant, SSRIs/SNRIs, gabapentin, CBT

Last reviewed: July 2026
Version: 1.0
Review cadence: Annually

At a Glance

The 30-second view

Effectiveness for hot flushes
Menopausal Hormone Therapy
Most effective available
Non-Hormonal Treatment
Effective, but less so
Protects bone
Menopausal Hormone Therapy
Yes
Non-Hormonal Treatment
No
Treats the cause
Menopausal Hormone Therapy
Yes — replaces the missing oestrogen
Non-Hormonal Treatment
No — works around it
Main limitation
Menopausal Hormone Therapy
Contraindicated in some women; small absolute risks
Non-Hormonal Treatment
Lower efficacy; own side effects
Suitable after breast cancer
Menopausal Hormone Therapy
Generally not
Non-Hormonal Treatment
Yes — this is where they matter most

Dimension	Menopausal Hormone Therapy	Non-Hormonal Treatment
Effectiveness for hot flushes	Most effective available	Effective, but less so
Protects bone	Yes	No
Treats the cause	Yes — replaces the missing oestrogen	No — works around it
Main limitation	Contraindicated in some women; small absolute risks	Lower efficacy; own side effects
Suitable after breast cancer	Generally not	Yes — this is where they matter most

Overview

Hormone therapy replaces what menopause removes, which is why it works better than anything else for vasomotor symptoms. Non-hormonal treatments work around the deficit instead. Both are legitimate; they are not equivalent.

Quick summary

Hormone therapy is the most effective treatment for hot flushes and night sweats, and it protects bone — nothing else does both. For most women under 60, or within 10 years of menopause, without contraindications, it is first-line, and its risks have been overstated for two decades. Non-hormonal options — NK3-receptor antagonists such as fezolinetant, certain SSRIs and SNRIs, gabapentin, and CBT — are genuinely effective and matter enormously for women who cannot take hormones, particularly after breast cancer. They are real treatments, not consolation prizes; they are simply less effective.

When each is appropriate

Choose Menopausal Hormone Therapy

Symptomatic, under 60 or within 10 years of menopause, without contraindications — the default for most women.

Choose Non-Hormonal Treatment

Contraindications to hormones (notably a history of breast cancer or thromboembolism), or a clear personal preference not to take them.

Evidence comparison

Hot flushes and night sweats
Menopausal Hormone Therapy
Most effective; large effect
Non-Hormonal Treatment
Effective; smaller effect
Bone loss and fractures
Menopausal Hormone Therapy
Prevents
Non-Hormonal Treatment
No effect
Genitourinary symptoms
Menopausal Hormone Therapy
Vaginal oestrogen — highly effective, minimal absorption
Non-Hormonal Treatment
Non-hormonal moisturisers — less effective
Breast cancer risk
Menopausal Hormone Therapy
Small increase with combined therapy; NOT increased with oestrogen alone in WHI
Non-Hormonal Treatment
No increase
Clot risk
Menopausal Hormone Therapy
Raised with oral; lower with transdermal
Non-Hormonal Treatment
No increase
Guideline status
Menopausal Hormone Therapy
First-line for vasomotor symptoms
Non-Hormonal Treatment
Recommended where hormones are unsuitable

Dimension	Menopausal Hormone Therapy	Non-Hormonal Treatment
Hot flushes and night sweats	Most effective; large effect	Effective; smaller effect
Bone loss and fractures	Prevents	No effect
Genitourinary symptoms	Vaginal oestrogen — highly effective, minimal absorption	Non-hormonal moisturisers — less effective
Breast cancer risk	Small increase with combined therapy; NOT increased with oestrogen alone in WHI	No increase
Clot risk	Raised with oral; lower with transdermal	No increase
Guideline status	First-line for vasomotor symptoms	Recommended where hormones are unsuitable

Safety comparison

Common issues
Menopausal Hormone Therapy
Breast tenderness, irregular bleeding, bloating; small absolute increases in clot and (with combined therapy) breast cancer risk
Non-Hormonal Treatment
SSRI/SNRI side effects; gabapentin sedation; fezolinetant requires liver monitoring

Dimension	Menopausal Hormone Therapy	Non-Hormonal Treatment
Common issues	Breast tenderness, irregular bleeding, bloating; small absolute increases in clot and (with combined therapy) breast cancer risk	SSRI/SNRI side effects; gabapentin sedation; fezolinetant requires liver monitoring

Strengths & limitations

Menopausal Hormone Therapy

The most effective treatment available for vasomotor symptoms

Prevents postmenopausal bone loss

Treats the cause rather than working around it

Vaginal oestrogen is highly effective for genitourinary symptoms with minimal systemic absorption

Contraindicated after breast cancer and in some clot and liver conditions

Small absolute increase in breast cancer risk with combined therapy, growing with duration

Requires periodic review

Non-Hormonal Treatment

Suitable for women who cannot take hormones, including after breast cancer

No breast cancer or clot risk

Fezolinetant is a genuine advance, targeting the mechanism of hot flushes directly

CBT has durable benefit and no pharmacological risk

Less effective than hormone therapy for hot flushes

No bone protection

Each option carries its own side-effect profile

Frequently asked questions

If hormone therapy is more effective, why would anyone choose the alternatives?

Because some women cannot safely take hormones — most importantly after breast cancer — and some simply prefer not to. For them, the non-hormonal options are not a fobbing-off: fezolinetant targets the mechanism of hot flushes directly, and CBT has durable benefit. Less effective is not the same as ineffective.

I'm scared of hormone therapy because of what I've read. Is that fear justified?

Mostly, no — and that matters, because two decades of women went untreated on the strength of it. The detail is important: in the landmark trial's oestrogen-only arm, breast cancer was not increased. The increase was seen with combined therapy and grew with duration, and in absolute terms it was small. For most women under 60, the benefits outweigh the risks. It is worth having the conversation properly rather than deciding from a headline.

Continue Exploring

Where to go next

References & sources

The Menopause Society position statement on hormone therapy
NICE guideline: Menopause
Fezolinetant randomised trials

Comparisons synthesize BioSignal's existing calibrated evidence — they introduce no new conclusions. Figures and verdicts trace to the linked Signal Records and Foundations.

Educational information — not medical advice

Comparisons orient a decision; they don't make it for you. Choices between medications, supplements, or programs belong with a qualified clinician. See our Medical Disclaimer.

Is this comparison clear, balanced, and useful? Your feedback shapes what we review next.

Give feedback